Search Results - "Fiscella, R"

Refine Results
  1. 1

    Intraocular Pressure and Medication Changes Associated with Xen Gel Stent: A Systematic Review of the Literature by Panarelli, Joseph F, Vera, Vanessa, Sheybani, Arsham, Radcliffe, Nathan, Fiscella, Richard, Francis, Brian A, Smith, Oluwatosin U, Noecker, Robert J

    Published in Clinical ophthalmology (Auckland, N.Z.) (01-01-2023)
    “…The Xen gel stent (Allergan Inc, an AbbVie company; Dublin, Ireland) was conceived as an option for patients requiring modest IOP reduction but for whom…”
    Get full text
    Journal Article
  2. 2

    Cost considerations of medical therapy for glaucoma by Fiscella, Richard G, Geller, Jennifer L, Gryz, Leanna L, Wilensky, Jacob, Viana, Marlos

    Published in American journal of ophthalmology (01-10-1999)
    “…PURPOSE: To determine the calculated daily patient cost (cost minimization) of medical glaucoma therapy. METHODS: The actual volume of various glaucoma…”
    Get full text
    Journal Article
  3. 3

    Aqueous and vitreous penetration of levofloxacin after oral administration by Fiscella, R G, Nguyen, T K, Cwik, M J, Phillpotts, B A, Friedlander, S M, Alter, D C, Shapiro, M J, Blair, N P, Gieser, J P

    Published in Ophthalmology (Rochester, Minn.) (01-12-1999)
    “…To investigate the penetration of levofloxacin, an optical S-(-)isomer of ofloxacin, into the aqueous and vitreous humor after oral administration. Randomized,…”
    Get more information
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitis by Skolnick, Craig A, Fiscella, Richard G, Tessler, Howard H, Goldstein, Debra A

    Published in American journal of ophthalmology (01-03-2000)
    “…PURPOSE: To report the use of intracameral tissue plasminogen activator to dissolve fibrinous membranes and break posterior synechiae in patients with acute…”
    Get full text
    Journal Article
  8. 8

    Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis by Rabiah, PK, Fiscella, RG, Tessler, HH

    “…To determine in rabbits whether periocular injection of ketorolac tromethamine effectively delivers the drug to the eye and, if so, whether this is efficacious…”
    Get full text
    Journal Article
  9. 9

    The effect of propranolol versus placebo on resident surgical performance by Elman, M J, Sugar, J, Fiscella, R, Deutsch, T A, Noth, J, Nyberg, M, Packo, K, Anderson, R J

    “…To determine whether propranolol can decrease surgical tremor and anxiety in residents performing ocular microsurgery without impairing patient or physician…”
    Get full text
    Journal Article
  10. 10

    Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa by Grover, S, Fishman, G A, Fiscella, R G, Adelman, A E

    Published in Retina (Philadelphia, Pa.) (1997)
    “…To compare the effectiveness of topical dorzolamide hydrochloride (Trusopt, Merck and Co., Inc., West Point, PA), a carbonic anhydrase inhibitor, with that of…”
    Get more information
    Journal Article
  11. 11

    Biotransformation in review: applications in ocular disease and drug design by Gaynes, B I, Fiscella, R G

    “…The purpose of this paper is to review the biochemical processes of systemic biotransformation and describe their relevance to ocular disease and drug…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Stability of cyclosporine 1% in artificial tears by Fiscella, R G, Le, H, Lam, T T, Labib, S

    “…We wished to determine the stability of frozen, refrigerated, and room temperature topical cyclosporine 1% in artificial tears (Tears Plus). Cyclosporine 1%…”
    Get more information
    Journal Article
  14. 14

    Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review by GAYNES, Bruce I, FISCELLA, Richard

    Published in Drug safety (2002)
    “…Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used agents that despite chemically heterogeneity, share similar therapeutic properties and adverse…”
    Get full text
    Journal Article
  15. 15

    Intraocular tissue plasminogen activator concentrations after subconjunctival delivery by Lim, J I, Maguire, A M, John, G, Mohler, M A, Fiscella, R G

    Published in Ophthalmology (Rochester, Minn.) (01-03-1993)
    “…Topical application of recombinant tissue plasminogen activator (tPA) results in detectable intraocular tPA levels. The authors sought to determine whether…”
    Get more information
    Journal Article
  16. 16

    Achromobacter xylosoxidans corneal ulcer in a therapeutic soft contact lens wearer by Fiscella, R, Noth, J

    Published in Cornea (01-12-1989)
    “…Achromobacter xylosoxidans is an opportunistic organism that is usually seen in immunocompromised or immunosuppressed patients. It is an aerobic gram-negative…”
    Get more information
    Journal Article
  17. 17
  18. 18

    Antimicrobial drug delivery to the eye by Lesar, T S, Fiscella, R G

    Published in Drug intelligence & clinical pharmacy (01-09-1985)
    “…A major obstacle in the treatment of ocular infections is the difficulty in obtaining adequate antimicrobial drug concentration at the site of infection. This…”
    Get more information
    Journal Article
  19. 19
  20. 20